Arazlo (tazarotene lotion) / Bausch Health - LARVOL DELTA

Drugs for acne. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Acne Vulgaris

A Practical Guide to Advanced Topical Drug Delivery Systems in Dermatology. (PubMed, Skin Therapy Lett) - "Awareness of the delivery system in which drugs are formulated is critical as this can have profound implications on treatment success. This paper provides an overview and clinical commentary on advances in topical delivery systems and their impact on dermatological practice."

Journal • Metastases • Acne Vulgaris • Atopic Dermatitis • Dermatitis • Dermatology • Immunology • Psoriasis

Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis (clinicaltrials.gov) - P=N/A | N=90 | Completed | Sponsor: Jinnah Postgraduate Medical Centre

New trial • Dermatology • Immunology • Psoriasis

Efficacy and Safety of Tazarotene Lotion, 0.045% in the Treatment of Truncal Acne Vulgaris. (PubMed, J Drugs Dermatol) - "Tazarotene lotion, 0.045% is shown to be effective and well-tolerated for the management of truncal acne in this pilot study. Further studies with placebo control and larger populations are warranted. J Drugs Dermatol. 2022;21(7):713-716. doi:10.36849/JDD.6967."

Journal • Acne Vulgaris • Dermatology • Pruritus

Clascoterone cream (Winlevi) for acne. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Acne Vulgaris

Drugs for acne. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • Acne Vulgaris • Infectious Disease • Novel Coronavirus Disease

ARAZLO Lotion: Tazarotene redefined (ON24) - Friday, January 15th, 2021, 12:00-1:00 PM ET.

Live event

[VIRTUAL] ARAZLO: Tazarotene Reformulated (FCDC 2020) - "sponsored by Ortho Dermatologics (non-CME)"

Dermatology

Once-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex - "The prevalence of adult acne appears to be increasing in both females and males; however, there are differences in treatment needs and physiology between the sexes that should be taken into account when prescribing acne treatments. While most patients experience onset during adolescence, persistent adult acne is more common in female patients....This easily spreadable and easy-to-use lotion formulation also allows for a lower tazarotene concentration, and when combined with optimized delivery of active and hydrating ingredients, may improve tolerability."

Clinical • P3 data

ARAZLO (Tazarotene 0.045%) Lotion for Topical Treatment of Acne Vulgaris. (PubMed, Skinmed) - No abstract available

Journal • Acne Vulgaris • Dermatology • Dermatopathology

"FDA approves tazarotene lotion 0.045% to treat #acne vulgaris for patients 9-years-old and up. https://t.co/DtRFbZRrZj" (@Medscape)

Clinical • FDA event

"FDA approves tazarotene lotion 0.045% to treat #acne vulgaris for patients 9-years-old and up. https://t.co/KKNMDT9RzO" (@Medscape)

Clinical • FDA event